Analysts have been eager to weigh in on the Healthcare sector with new ratings on Eli Lilly & Co (NYSE:LLY) and Verastem (NASDAQ:VSTM).
Eli Lilly & Co (LLY)
BMO Capital analyst Alex Arfaei maintained a Hold rating on Eli Lilly & Co today and set a price target of $90. The company’s shares opened today at $105.67, close to its 52-week high of $106.49.
According to TipRanks.com, Arfaei is a 4-star analyst with an average return of 7.4% and a 69.6% success rate. Arfaei covers the Healthcare sector, focusing on stocks such as Merck & Company, Bristol Myers, and AstraZeneca.
Currently, the analyst consensus on Eli Lilly & Co is a Moderate Buy with an average price target of $99.22.
See today’s analyst top recommended stocks >>
Verastem (VSTM)
In a report released today, Leah R. Cann from Oppenheimer initiated coverage with a Buy rating on Verastem and a price target of $16. The company’s shares opened today at $9.25, close to its 52-week high of $10.35.
Cann noted:
“If this phase I/II study can confirm that the combination of Duvelisib and venetoclax is well tolerated and improves the complete response rate over either agent alone, it could lead to the use of Duvelisib in earlier lines of treatment than currently being evaluated. While preclinical data support this combination, we are not adjusting our outlook at this time due to the timing and phase of this new study.”
According to TipRanks.com, Cann is a 5-star analyst with an average return of 23.7% and a 53.7% success rate. Cann covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, Miragen Therapeutics Inc, and CytomX Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Verastem with a $14.38 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on VSTM:
